The FDA's drugs and biologics center directors said lessons from the rare disease “mindset shift” could be leveraged for ...
Genmab’s rinatabart sesutecan (Rina-S) reduced risk of disease progression by 71% and risk of death by 57% in platinum-resistant ovarian cancer (PROC) regardless of FRα expression, a competitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results